CA 125 (Dako Omnis)

Clone M11

Recognizes a mucin-like glycoprotein larger than 200 kDa, expressing the CA 125 epitope. The antibody is a useful aid for classification of a variety of tumors, such as some adenocarcinomas of the colon, breast carcinomas, malignant mesothelioma, uterine adenomatoid tumor, lung bronchoalveolar carcinoma, and ovarian endometrioid and serous carcinomas. Results may also aid in the classification of adenocarcinomas (1).

Monoclonal Mouse Anti-Human

Features

Optimized staining performance of both high and low-expression structures
Dako Omnis and the dynamic gap staining technology provides a consistent, uniform staining with excellent morphology
Crisp and clear staining with no background
Optimal laboratory efficiency with ready-to-use antibodies on Dako Omnis
The staining performance of all FLEX RTU antibodies has been defined, tested and approved through collaboration with leading, international pathology experts.

Specifications


Application	Formalin HIER
Clone	M11
Code Number	GA701
Immunogen	CA 125 antigen derived from ascites fluid.
Isotype	IgG1, kappa
Reagent Provided	Ready-to-use monoclonal mouse antibody provided in liquid form in a buffer containing stabilizing protein and 0.015 mol/L sodium azide.
Solutions	Dako Omnis
Species	Mouse Anti-Human
Specificity	In Western blotting, the antibody labels multiple antigenic species including the molecular species recognized by monoclonal anti-CA 125, clone OC125 (7). Competition assays have demonstrated that monoclonal antibody clone M11 does not compete with monoclonal antibody clone OC125 for binding to the CA 125 antigen (7). See package insert for reference(s).

Return to top

Featured References

Product Description References: 1. Neal S. Goldstein, MD. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002,117:471-7.

Featured

CA 125 (Dako Omnis)

Product Details

Atlas of Controls

View supported Instructions For Use documents

1. Neal S. Goldstein, MD. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002,117:471-7.

Customers Also Viewed These Products